Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report)’s stock price passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $0.07 and traded as high as $0.0792. Mateon Therapeutics shares last traded at $0.0792, with a volume of 12,541 shares.
Mateon Therapeutics Price Performance
The company has a fifty day moving average price of $0.09 and a 200 day moving average price of $0.07. The stock has a market cap of $7.15 million, a P/E ratio of -3.96 and a beta of 1.33.
Mateon Therapeutics Company Profile
Mateon Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision oncology therapies that selectively target tumor tissue. The company’s platform leverages tumor-activated peptides designed to bind to the fibrin–fibronectin complexes uniquely present in solid tumors, with the goal of improving the therapeutic index of cytotoxic payloads while limiting off-target effects.
Its lead asset, MH1, is a peptide–drug conjugate in Phase I clinical trials for advanced solid tumors.
Featured Articles
- Five stocks we like better than Mateon Therapeutics
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- Buy This Stock at 9:30 AM on MONDAY!
- Nvidia CEO Issues Bold Tesla Call
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
